Maynard Um
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Lowered to $32 at Leerink Partners
-
-
-
-
-
-
-
Intellia begins rolling FDA submission for gene editing therapy
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $27 at Chardan
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Intellia Therapeutics (NTLA)
-
-
-
-
-
-
-
Evercore ISI Downgrades Intellia Therapeutics (NTLA) to In Line
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird
-
-
-
-
-
-
-
RBC Capital Downgrades Intellia Therapeutics (NTLA) to Sector Perform
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

